Merck Millipore

Masimo Announces New Member of the Board of Directors

Retrieved on: 
Tuesday, November 7, 2023
Medical Devices, Health, Technology, Health Technology, Cardiology, Auxilium, Pharmacia, Mayo Collaborative Services v. Prometheus Laboratories, Inc., BICO Group, Catalent, Chemical engineering, MASI, Chemical substance, Vice, Business, Perrigo, Central Executive Committee of the Pakistan Peoples Party, Merck Millipore, Supervisory board, Gothenburg University Library, Executive Committee, University of Gothenburg, Gothenburg School of Business, Economics and Law, Retirement, Management, Engineering

Masimo (NASDAQ: MASI) announced today that Rolf A. Classon has been appointed to Masimo’s Board of Directors.

Key Points: 
  • Masimo (NASDAQ: MASI) announced today that Rolf A. Classon has been appointed to Masimo’s Board of Directors.
  • Mr. Classon is an experienced medical technology executive and board member.
  • Mr. Classon was previously Chairman of the Board of Directors of Perrigo Company plc, Chairman of the Board of Directors of Tecan Group Ltd., Chairman of the Board of Directors of Hill-Rom Corporation, and Chairman of the Board of Directors of Auxilium Pharmaceuticals, Inc.
  • Joe Kiani, Chairman and CEO of Masimo, said, “We’re happy to welcome Rolf to our Board.

Global Single Use Bioreactors Markets, 2023-2035 - Rising Interest in Large Scale Disposable Bioreactors for Single use Bioprocessing - ResearchAndMarkets.com

Retrieved on: 
Monday, October 23, 2023
Security, Health, Technology, Other Technology, Pharmaceutical, Biotechnology, Type, Water, USFDA, Merck Millipore, Pressure, Food and Bioprocess Technology, Compound, Merck, Growth, Cell culture, Eppendorf, Medicine, Risk, Thermo Fisher Scientific, Safety, CMOS, ABEC, Fine chemical, Sewage treatment, Bioreactor

Single use Bioreactor Market Size: Stirred Tank Single-Use Bioreactor Segment holds the Largest Market Share

Key Points: 
  • Single use Bioreactor Market Size: Stirred Tank Single-Use Bioreactor Segment holds the Largest Market Share
    The global single use bioreactors market is likely to be worth around USD 1.3 billion in 2023.
  • Currently, the global market for single-use bioreactors is dominated by companies providing stirred tank bioreactors.
  • The global market for single use bioreactors is anticipated to witness substantial growth during the forecast period.
  • It is worth highlighting that majority of the single use bioreactors (~60%) offered by various manufacturers are stirred tank bioreactors.

Nirrin appoints Greg Crescenzi as Chief Executive Officer

Retrieved on: 
Tuesday, October 10, 2023
Hardware, Semiconductor, Data Management, Manufacturing, Technology, Nanotechnology, General Health, Other Technology, Other Manufacturing, Science, Software, Other Science, Health, Engineering, Research, Multimedia, Cell, Business Leaders for Michigan, STEP, MIT, Improper integral, Bioprocess, Merck Millipore, Management

Nirrin Technologies , a company developing analytical systems to transform analysis for bioprocessing operations, announced that Greg Crescenzi has joined the company as its Chief Executive Officer.

Key Points: 
  • Nirrin Technologies , a company developing analytical systems to transform analysis for bioprocessing operations, announced that Greg Crescenzi has joined the company as its Chief Executive Officer.
  • View the full release here: https://www.businesswire.com/news/home/20231010407829/en/
    “Greg brings 30 years of strategic leadership in life science and biomanufacturing, and a long-standing history in commercializing industry-first tools and technologies,” said Matt Gunnison, CEO of Gamma Biosciences, a Nirrin strategic investor.
  • While at Cytiva he also served as Business Leader for Cell Culture Services, Xcellerex and Microcarriers, launching flagship products and quadrupling revenue.
  • I’m excited to see how our new STEP program partners utilize the HPTLS platform to speed time to answer in their own bioprocesses,” said Greg Crescenzi, CEO of Nirrin.

Osmoses Secures $11M to Decarbonize Projected $35B Industrial Gas Separation Market with Novel Membrane Technology

Retrieved on: 
Tuesday, October 3, 2023
Technology, Other Natural Resources, Other Energy, Other Technology, Natural Resources, Green Technology, Oil, Gas, Alternative Energy, Environment, Energy, Sustainability, Merck Millipore, U.S. Department of Energy, Office of Inspector General, Science, Collaborative Fund, U.S. Department of Defense Strategy for Operating in Cyberspace, Associate professor, Hydrogen, NSF, Oxygen, Distillation, Multimedia, Carbon, DOE, IRA, Doctor of Philosophy, ARPA, Organization, Membrane, Inflation, Chemical substance, Climate change, MIT Department of Mathematics, Inflation Reduction Act of 2022, Chemical engineering, Family, CO2, Natural gas, Renewable energy, Engineering, Science (journal), Osmose New Zealand Ltd v Wakeling

Osmoses will use the funding to develop commercial scale membrane modules for field deployment and establish pilot partnerships.

Key Points: 
  • Osmoses will use the funding to develop commercial scale membrane modules for field deployment and establish pilot partnerships.
  • Today’s industrial separation processes, including cryogenic processes, distillation, and solvent absorption, account for 15% of the world’s energy consumption .
  • CO2 emissions from energy combustion and industrial processes accounted for 89% of energy-related greenhouse gas emissions in 2022.
  • Osmoses can also power profitable hybrid separation system designs for low feed concentrations such as those in hydrogen de-blending and helium recovery.

Global Single Use Bioreactors Research Report 2023-2028: Startups and SMEs Embrace Single-Use Bioreactors - Adoption Surges as Complexity Decreases - ResearchAndMarkets.com

Retrieved on: 
Monday, July 31, 2023
Biotechnology, Pharmaceutical, Health, Biometrics, Molecule, Hook effect, CMOS, Sartorius AG, Research, Thermo Fisher Scientific, USD, Danaher Corporation, Bioreactor, Government, Pulse, Merck Millipore, Investment, Water, Filtration, Growth, Region, ChromeOS, SME, Fine chemical, Landfill, Vaccine

The major factors driving the growth of this market include the increasing adoption of single-use bioreactors among startups and SMEs, reduced operational complexity of single-use bioreactors compared to conventional bioreactors, lower energy and water consumption, growing biologics and biosimilars market, and technological advancements in single-use bioreactors.

Key Points: 
  • The major factors driving the growth of this market include the increasing adoption of single-use bioreactors among startups and SMEs, reduced operational complexity of single-use bioreactors compared to conventional bioreactors, lower energy and water consumption, growing biologics and biosimilars market, and technological advancements in single-use bioreactors.
  • This report provides a detailed picture of the single-use bioreactors market.
  • Based on application, the single-use bioreactors market is segmented into research & development, process development, and bioproduction.
  • Based on end users, the single-use bioreactors market is segmented into pharmaceutical & biotechnology companies, CROs & CMOs, and academic & research institutes.

Global Mesenchymal Stem Cells / Medicinal Signaling Cells (MSCs) Strategic Research Report 2023: Activities of 110+ Leading MSC Companies, Including their Core Technologies and Products - ResearchAndMarkets.com

Retrieved on: 
Friday, April 7, 2023
Health, Stem Cells, Therapy, Humanities Advanced Technology and Information Institute, 3D, COVID-19, Exosome, ATCC, Research, Thermo Fisher Scientific, Adipocyte, Merck Millipore, Microsoft Exchange Server, Biotechnology, Regenerative medicine, EVS, Osteoblast, Gene editing, Seminal vesicles, MSC, Cosmeceutical, Chondrocyte, Patient, Sartorius, Geography, Stem cell, VWR, Gene, Safety, Pharmaceutical industry, Fishing, Retail

The "Mesenchymal Stem Cells / Medicinal Signaling Cells (MSCs) - Advances & Applications, 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Mesenchymal Stem Cells / Medicinal Signaling Cells (MSCs) - Advances & Applications, 2023" report has been added to ResearchAndMarkets.com's offering.
  • MSCs are multipotent cells that can differentiate into a variety of cell types, including but not limited to osteoblasts, chondrocytes, myocytes, and adipocytes.
  • Therefore, this global strategic report details the activities of 113 leading MSC companies, including their core technologies and products under development.
  • This global strategic report includes:
    Market size determination for the global MSC market, segmented by Geography and Business Segment
    Recent business developments related to MSCs, including strategic collaborations and partnerships
    Company profiles for MSC market competitors, including their products, services, and technologies under development

The Global Cancer Biomarkers Market to Upsurge at a Tremendous CAGR of ~14% by 2027 | DelveInsight

Retrieved on: 
Monday, February 13, 2023
Medicine, Colon, Smoking, Abbott Laboratories, Agilent Technologies, Cancer, Neurology, Quest Diagnostics, OncoDNA, Merck Millipore, Lung cancer, Sysmex Corporation, Collection, Minerva Surgical, Inc. v. Hologic, Inc., Roche, Biomarker, Emergency, Oncology, PerkinElmer, Prostate cancer, FDA, Growth, Illumina, Inc., Prevalence, AstraZeneca, US Foods, LAS, R, BD, Helmy Eltoukhy, TK1, United Kingdom, Immunotherapy, MBC, Diagnosis, Breast cancer, Myriad Genetics, Data analysis, Patient, Research, Cell proliferation, Risk, Serum, COVID-19, NSCLC, Stomach cancer, PD-L1, QIAGEN, Siemens Healthineers, Exact sciences, Prognosis, Dietary supplement, Oil, Pharmaceutical industry, Medical imaging

LAS VEGAS, Feb. 13, 2023 /PRNewswire/ -- DelveInsight's Cancer Biomarkers Market Insights report provides the current and forecast market analysis, individual leading cancer biomarkers companies' market shares, challenges, cancer biomarkers market drivers, barriers, and trends, and key cancer biomarkers companies in the market.

Key Points: 
  • LAS VEGAS, Feb. 13, 2023 /PRNewswire/ -- DelveInsight's Cancer Biomarkers Market Insights report provides the current and forecast market analysis, individual leading cancer biomarkers companies' market shares, challenges, cancer biomarkers market drivers, barriers, and trends, and key cancer biomarkers companies in the market.
  • As per DelveInsight estimates, North America is anticipated to dominate the global cancer biomarkers market during the forecast period.
  • To read more about the latest highlights related to the cancer biomarkers market, get a snapshot of the key highlights entailed in the Global Cancer Biomarkers Market Report
    Cancer biomarkers are biological molecules that aid in the detection of cancer in patients.
  • To know more about why North America is leading the market growth in the cancer biomarkers market, get a snapshot of the Cancer Biomarkers Market Outlook
    One of the major factors driving the growth of the cancer biomarkers market is the global increase in the prevalence of various types of cancer.

The Global Cancer Biomarkers Market to Upsurge at a Tremendous CAGR of ~14% by 2027 | DelveInsight

Retrieved on: 
Monday, February 13, 2023
Medicine, Colon, Smoking, Abbott Laboratories, Agilent Technologies, Cancer, Neurology, Quest Diagnostics, OncoDNA, Merck Millipore, Lung cancer, Sysmex Corporation, Collection, Minerva Surgical, Inc. v. Hologic, Inc., Roche, Biomarker, Emergency, Oncology, PerkinElmer, Prostate cancer, FDA, Growth, Illumina, Inc., Prevalence, AstraZeneca, US Foods, LAS, R, BD, Helmy Eltoukhy, TK1, United Kingdom, Immunotherapy, MBC, Diagnosis, Breast cancer, Myriad Genetics, Data analysis, Patient, Research, Cell proliferation, Risk, Serum, COVID-19, NSCLC, Stomach cancer, PD-L1, QIAGEN, Siemens Healthineers, Exact sciences, Prognosis, Dietary supplement, Oil, Pharmaceutical industry, Medical imaging

LAS VEGAS, Feb. 13, 2023 /PRNewswire/ -- DelveInsight's Cancer Biomarkers Market Insights report provides the current and forecast market analysis, individual leading cancer biomarkers companies' market shares, challenges, cancer biomarkers market drivers, barriers, and trends, and key cancer biomarkers companies in the market.

Key Points: 
  • LAS VEGAS, Feb. 13, 2023 /PRNewswire/ -- DelveInsight's Cancer Biomarkers Market Insights report provides the current and forecast market analysis, individual leading cancer biomarkers companies' market shares, challenges, cancer biomarkers market drivers, barriers, and trends, and key cancer biomarkers companies in the market.
  • As per DelveInsight estimates, North America is anticipated to dominate the global cancer biomarkers market during the forecast period.
  • To read more about the latest highlights related to the cancer biomarkers market, get a snapshot of the key highlights entailed in the Global Cancer Biomarkers Market Report
    Cancer biomarkers are biological molecules that aid in the detection of cancer in patients.
  • To know more about why North America is leading the market growth in the cancer biomarkers market, get a snapshot of the Cancer Biomarkers Market Outlook
    One of the major factors driving the growth of the cancer biomarkers market is the global increase in the prevalence of various types of cancer.

Repligen Appoints Martin D. Madaus to Board of Directors

Retrieved on: 
Thursday, February 9, 2023
Repligen Corporation Award in Chemistry of Biological Processes, Aptitude, Merck Millipore, Repligen, Ortho Clinical Diagnostics, Martin, Acquisition, Merck Group, The Carlyle Group, Veterinary medicine, Technical University of Munich, University, Lead, Covidien, AG, Growth, Doctor of Philosophy, Management

WALTHAM, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences tools industry leader Martin D. Madaus.

Key Points: 
  • WALTHAM, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences tools industry leader Martin D. Madaus.
  • He is an active board leader, currently serving two public companies; as Lead Director for precision health technology company Quanterix Corporation and as Board member for mass cytometry player Standard BioTools, Inc. (previously Fluidigm Corporation).
  • Karen A. Dawes, Chairperson of the Board of Directors for Repligen, said, “We are thrilled to welcome Dr. Madaus to the Repligen board, as the company continues to drive innovation in bioprocessing and expand into new markets.
  • Hunt, President and Chief Executive Officer said, “I’m excited for this opportunity to work more closely with Martin.

eGenesis Announces Knut Niss as Chief Technology Officer

Retrieved on: 
Tuesday, January 24, 2023
Cell, Mustang, Molecular biology, Regenerative medicine, Biotechnology, CMC, Hospital, Biogen, Organ transplantation, Manifest and latent functions and dysfunctions, Humboldt University of Berlin, Patient, Cell therapy, Dana–Farber Cancer Institute, University of Göttingen, Doctor of Philosophy, Merck Millipore, Pharmaceutical industry, Operation, Biology, Pfizer

CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced that Knut Niss, Ph.D., has joined the company as Chief Technology Officer.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced that Knut Niss, Ph.D., has joined the company as Chief Technology Officer.
  • “We are pleased to welcome Knut to the team and are confident he will help us advance our goal of transforming the treatment paradigm for organ failure,” said Michael Curtis, Ph.D., Chief Executive Officer of eGenesis.
  • “Synthetic biology and gene engineering are core components of our approach to developing high-quality, transplantable organs that ultimately save lives.
  • “Powered by a strong technological platform, eGenesis is well-positioned to address the hurdles that have hindered the field of xenotransplantation to date,” Dr. Niss said.